PF 6700841

Drug Profile

PF 6700841

Alternative Names: PF-06700841; PF-6700841

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antipsoriatics
  • Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase Unknown Alopecia areata; Ulcerative colitis
  • Discontinued Lupus vulgaris

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Plaque psoriasis in USA (PO) (NCT02969018)
  • 23 Nov 2016 Investigation in Alopecia areata in USA (PO) before November 2016
  • 23 Nov 2016 Pfizer plans a phase IIa trial for Alopecia areata in USA (PO) (NCT02974868)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top